RESEARCH TRIANGLE PARK – TransEnterix wants to expand the use of its robotic surgery system and is seeking FDA approval to do so.

The company hopes that its Senhance Surgical System will be ok’d for use in general surgery.

Senhance is currently limited to “aparoscopic gynecological surgery, colorectal surgery, cholecystectomy, and inguinal hernia repair. The system is indicated for adult use. It is intended for use by trained physicians in an operating room environment in accordance with the Instructions for Use.,” the company says.

“This submission is an important milestone for the continued application of Senhance in the highest volume and value procedures,” said Anthony Fernando, chief executive officer at TransEnterix. “General Surgery is by far the largest procedural area in minimally invasive abdominal surgery, and we are pleased to have submitted significant additional clinical data to expand the procedures for which surgeons can utilize the benefit of Senhance.”

More recent TransEnterix coverage in TechWire

CEO is out at TransEnterix, will remain an adviser as company mulls possible sale

RTP-based robotic device firm TransEnterix lands $25M stock deal

Robotic surgery firm TransEnterix looks to raise $13M; stock price plunges